Heart Test Laboratories, Inc. Share Price

Equities

HSCS

US42254E3027

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:00:00 17/05/2024 BST 5-day change 1st Jan Change
6.97 USD -38.37% Intraday chart for Heart Test Laboratories, Inc. -20.80% -59.24%
Sales 2024 * 59.3K 4.67M Sales 2025 * 1.9M 150M Capitalization 4.57M 360M
Net income 2024 * -6M -472M Net income 2025 * -9M -709M EV / Sales 2024 * 77.1 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.41 x
P/E ratio 2024 *
-0.35 x
P/E ratio 2025 *
-0.66 x
Employees 12
Yield 2024 *
-
Yield 2025 *
-
Free-Float 83.99%
More Fundamentals * Assessed data
Dynamic Chart
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG CI
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients CI
Heart Test Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
Heart Test Laboratories, Inc. Appoints Partho P. Sengupta to Its Scientific Advisory Board CI
Heart Test Laboratories, Inc. Appoints Jordan B. Strom to Its Scientific Advisory Board CI
HeartSciences Appoints Benjamin Glicksberg to its Scientific Advisory Board CI
Heart Test Laboratories, Inc. has Changed its Name to HeartSciences Inc CI
Heart Test Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023 CI
Heart Test Laboratories, Inc. announced that it has received $0.934997 million in funding CI
Heart Test Laboratories, Inc. announced that it has received $1.085006 million in funding CI
Heart Test Laboratories, Inc. Enters into Multiple Definitive License Agreements with Icahn School of Medicine At Mount Sinai CI
HeartSciences Completes License Agreements on AI Cardiovascular Algorithms With Icahn School of Medicine at Mount Sinai MT
Heart Test Laboratories, Inc. announced that it expects to receive $0.934997 million in funding CI
Heart Test Laboratories, Inc. announced that it expects to receive $1.085006 million in funding CI
Heart Test Laboratories, Inc. Announces That Its Myovista® Wavecgtm Has Been Selected by Cardiact Ltd (?Cardiact?) to Be Used in Its Heart Screening Program of Members of the Association of Garda Sergeants and Inspectors CI
More news
1 day-38.37%
1 week-20.80%
Current month-24.57%
1 month-30.99%
3 months-44.99%
6 months-57.94%
Current year-59.24%
More quotes
1 week
6.81
Extreme 6.81
13.50
1 month
6.81
Extreme 6.81
13.50
Current year
6.81
Extreme 6.81
18.50
1 year
6.81
Extreme 6.81
128.00
3 years
6.81
Extreme 6.81
600.00
5 years
6.81
Extreme 6.81
600.00
10 years
6.81
Extreme 6.81
600.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 24/07/13
Director of Finance/CFO 42 31/10/21
Chief Tech/Sci/R&D Officer - 30/06/14
Members of the board TitleAgeSince
Chief Operating Officer 66 24/07/13
Director/Board Member 61 27/12/22
Chief Executive Officer 55 24/07/13
More insiders
Date Price Change Volume
17/05/24 6.97 -38.37% 347,903
16/05/24 11.31 +25.81% 411,195
15/05/24 8.99 +13.65% 74,210
14/05/24 7.91 +12.04% 31,975
13/05/24 7.06 -19.77% 53,607

Delayed Quote Nasdaq, May 17, 2024 at 09:00 pm

More quotes
Heart Test Laboratories, Inc., doing business as HeartSciences, is an artificial intelligence electrocardiogram (AI ECG) company. The Company is focused on using AI to transform ECG to save lives through earlier detection of heart disease. The Company’s initial focus is on applying technology to extend the clinical indications for use of an electrocardiograph (ECG) device. Its first device, the MyoVista is an ECG that can be used in a range of clinical settings and provides diagnostic information to a qualified healthcare professional on cardiac dysfunction which has traditionally only been provided using cardiac imaging. In addition, MyoVista provides conventional ECG information. The Company focuses on marketing its device both domestically and internationally to various hospitals, clinics, and medical centers and manufacturing the devices using outsourced production facilities.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.97 USD
Average target price
67.5 USD
Spread / Average Target
+868.44%
Consensus